Stmc-09. assessment of tumorigenic potential of human induced pluripotent stem cell-derived neural stem/progenitor cells

DISCUSSION:Our research group is working vigorously to pursue a clinical trial for patients with SCI within the next several years. Therefore, it is crucial to establish criteria to choose the "safe" iPSC-NS/PCs. Here, we revealed differences in their SNVs, CNVs and DNA methylation patterns, which enables us to control the quality of iPSC-NS/PCs with respect to their tumorigenicity.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Iida, T., Iwanami, A., Kohyama, J., Nagoshi, N., Matsumoto, M., Okano, H., Nakamura, M. Tags: STEM CELLS Source Type: research